HomeCompareTRHC vs ABBV

TRHC vs ABBV: Dividend Comparison 2026

TRHC yields 19.05% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $33.5K in total portfolio value· pulled ahead in Year 8
10 years
TRHC
TRHC
● Live price
19.05%
Share price
$10.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$68.9K
Annual income
$6,079.53
Full TRHC calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TRHC vs ABBV

📍 ABBV pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRHCABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRHC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRHC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRHC
Annual income on $10K today (after 15% tax)
$1,619.05/yr
After 10yr DRIP, annual income (after tax)
$5,167.60/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $15,888.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRHC + ABBV for your $10,000?

TRHC: 50%ABBV: 50%
100% ABBV50/50100% TRHC
Portfolio after 10yr
$85.6K
Annual income
$15,425.65/yr
Blended yield
18.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TRHC
Analyst Ratings
1
Strong
11
Buy
8
Hold
Consensus: Buy
Price Target
$3.00
-71.4% upside vs current
Range: $3.00 — $3.00
Altman Z
-0.7
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRHC buys
0
ABBV buys
0
No recent congressional trades found for TRHC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRHCABBV
Forward yield19.05%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$68.9K$102.3K
Annual income after 10y$6,079.53$24,771.77
Total dividends collected$38.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$3.00$256.15

Year-by-year: TRHC vs ABBV ($10,000, DRIP)

YearTRHC PortfolioTRHC Income/yrABBV PortfolioABBV Income/yrGap
1$12,605$1,904.76$11,550$430.00+$1.1KTRHC
2$15,731$2,243.84$13,472$627.96+$2.3KTRHC
3$19,449$2,617.14$15,906$926.08+$3.5KTRHC
4$23,835$3,024.07$19,071$1,382.55+$4.8KTRHC
5$28,967$3,463.51$23,302$2,095.81+$5.7KTRHC
6$34,928$3,933.88$29,150$3,237.93+$5.8KTRHC
7$41,806$4,433.18$37,536$5,121.41+$4.3KTRHC
8← crossover$49,692$4,959.03$50,079$8,338.38$387.00ABBV
9$58,679$5,508.79$69,753$14,065.80$11.1KABBV
10$68,866$6,079.53$102,337$24,771.77$33.5KABBV

TRHC vs ABBV: Complete Analysis 2026

TRHCStock

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems. The company also provides TruChart that offers electronic health records (EHR), care coordination, and financial management in one program allowing Programs of All-Inclusive Care for the Elderly (PACE) to track measurable outcomes in defined timeframes for the populations they serve; and PACElogic, which delivers sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state that requires reporting. In addition, it offers DoseMeRx, a decision support software that leverages clinically validated pharmacokinetic drug models, patient characteristics, drug concentrations, and genotypes to guide dose optimization; and PrescribeWellness, a PrescribeWellness, a patient engagement center platform. Further, the company provides clinical pharmacist collaboration, prescription fulfillment and adherence packaging, and pharmacy benefit management services, as well as health plan management services, including risk adjustment and third party administrator services. As of December 31, 2021, it served approximately 150 healthcare organizations; and 350 health plans and approximately 18,000 retail pharmacies. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.

Full TRHC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TRHC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRHC vs SCHDTRHC vs JEPITRHC vs OTRHC vs KOTRHC vs MAINTRHC vs JNJTRHC vs MRKTRHC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.